Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide

Haematologica

Volumn 98, Issue 11, 2013, Pages 1677-1685

  Ferrer, Ruben A ^a   Wobus, Manja ^a   List, Catrin ^a   Wehner, Rebekka ^b   Schönefeldt, Claudia ^a   Brocard, Barbara ^a   Mohr, Brigitte ^a   Rauner, Martina ^a   Schmitz, Marc ^b,c   Stiehler, Maik ^a   Ehninger, Gerhard ^a,c   Hofbauer, Lorenz C ^a,c   Bornhäuser, Martin ^a,c   Platzbecker, Uwe ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ANGIOPOIETIN 1; BETA1 INTEGRIN; CD146 ANTIGEN; CD34 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CXCR4; ENDOGLIN; IMID; LENALIDOMIDE; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; THY 1 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MALE; MESENCHYMAL STROMA CELL; MICROENVIRONMENT; MYELODYSPLASTIC SYNDROME; REAL TIME POLYMERASE CHAIN REACTION;

AGED; CELL PROLIFERATION; COCULTURE TECHNIQUES; COHORT STUDIES; FEMALE; HUMANS; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; THALIDOMIDE;

EID: 84886998745     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.083972     Document Type: Article

References (50)

1. Vardiman J. The classification of MDS: from FAB to WHO and beyond. Leuk Res. 2012; 36(12): 1453-8.
2. Nimer SD. Myelodysplastic syndromes. Blood. 2008; 111(10): 4841-51.
3. BejarR, Levine R, Ebert BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol. 2011; 29(5): 504-15.
4. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006; 355(14): 1456-65.
5. Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennet JM, Deeg HJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, lowrisk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008; 111(1): 86-93.
6. Ishibashi M, Tamura H, Ogata K. Disease progression mechanism in myelodysplastic syndromes: insight into the role of the microenvironment. Leuk Res. 2011; 35(11): 1449-52.
7. Raza A, Cruz R, Latif T, Mukherjee S, Galili N. The biology of myelodysplastic syndromes: unity despite heterogeneity. Hematol Rep. 2010; 2(1): e4.
8. Raaijmakers MH. Niche contributions to oncogenesis: emerging concepts and implications for the hematopoietic system. Haematologica. 2011; 96(7): 1041-8.
9. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res. 2006; S 66(9): 4553-7.
10. Raaijmakers MH, Mukherjee S, Guo S, Zhang S, Kobayash T, Schoonmaker JA, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 2010; 464(7290): 852-7.
11. Walkley CR, Olsen GH, Dworkin S, Fabb SA, Swann J, McArthur GA, et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. Cell. 2007; 129(6): 1097-110.
12. Deeg HJ. Marrow stroma in MDS: culprit or bystander? Leuk Res. 2002; 26(7): 687-8.
13. Omatsu Y, Sugiyama T, Kohara H, Kondoh G, Fujii N, Kohno K, et al. The essential functions of adipo-osteogenic progenitors as the hematopoietic stem and progenitor cell niche. Immunity. 2010; 33(3): 387-99.
14. Mendez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010; 466(7308): 829-34.
15. Lo Celso C, Scadden DT. The hematopoietic stem cell niche at a glance. J Cell Sci. 2011; 124: 3529-35.
16. Zhao S, Wehner R, Bornhäuser M, Wassmuth R, Bachmann M, Schmitz M. Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells Dev. 2010; 19(5): 607-14.
17. Zhao Z, Wang Z, Li Q, Li W, You Y, Zou P. The different immunoregulatory functions of mesenchymal stem cells in patients with lowrisk or high-risk myelodysplastic syndromes. PLoS One. 2012; 7(9): e45675.
18. Wobus M, Benath G, Ferrer RA, Wehner R, Schmitz M, Hofbauer LC, et al. Impact of lenalidomide on the functional properties of human mesenchymal stromal cells. Exp Hematol. 2012; 40(10): 867-76.
19. Kerbauy DB, Deeg HJ. Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol. 2007; 35(11): 1739-46.
20. Soenen-Cornu V, Tourino C, Bonnet ML, Guillier M, Flamant S, Kotb R, et al. Mesenchymal cells generated from patients with myelodysplastic syndromes are devoid of chromosomal clonal markers and support short-and long-term hematopoiesis in vitro. Oncogene. 2005; 24(15): 2441-8.
21. Sarugaser R, Hanoun L, Keating A, Stanford WL, Davies JE. Human mesenchymal stem cells self-renew and differentiate according to a deterministic hierarchy. PLoS One. 2009; 4 (8): e6498.
22. Klaus M, Stavroulaki E, Kastrinaki MC, Fragioudaki P, Giannikou K, Psyllaki M, et al. Reserves, functional, immunoregulatory, and cytogenetic properties of bone marrow mesenchymal stem cells in patients with myelodysplastic syndromes. Stem Cells Dev. 2010; 19(7): 1043-54.
23. Kastrinaki MC, Pontikoglou C, Klaus M, Stavroulaki E, Pavlaki K, Papadaki HA. Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes. Curr Stem Cell Res Ther. 2011; 6(2): 122-30.
24. Lopez-Villar O, Garcia JL, Sanchez-Guijo FM, Robledo C, Villaron EM, Hernández-Campo P, et al. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q-syndrome. Leukemia. 2009; 23(4): 664-72.
25. Varga G, Kiss J, Várkonyi J, Vas V, Farkas P, Pálóczi K, Uher F. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes. Pathol Oncol Res. 2007; 13(4): 311-9.
26. Aanei CM, Flandrin P, Eloae FZ, Carasevici E, Guyotat D, Wattel E, et al. Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes. Stem Cells Dev. 2012; 21(10): 1604-15.
27. Aanei CM, Eloae FZ, Flandrin-Gresta P, Tavernier E, Carasevici E, Guyotat D, et al. Focal adhesion protein abnormalities in myelodysplastic mesenchymal stromal cells. Exp Cell Res. 2011; 317(18): 2616-29.
28. Jones E, McGonagle D. Human bone marrow mesenchymal stem cells in vivo. Rheumatology (Oxford). 2008; 47(2): 126-31.
29. Halfon S, Abramov N, Grinblat B, Ginis I. Markers distinguishing mesenchymal stem cells from fibroblasts are downregulated with passaging. Stem Cells Dev. 2011; 20 (1): 53-66.
30. Campioni D, Moretti S, Ferrari L, Punturieri M, Castoldi GL, Lanza F. Immunophenotypic heterogeneity of bone marrow-derived mesenchymal stromal cells from patients with hematologic disorders: correlation with bone marrow microenvironment. Haematologica. 2006; 91(3): 364-8.
31. Mellibovsky L, Diez A, Serrano S, Aubia J, Pérez-Vila E, Mariñoso ML, et al. Bone remodeling alterations in myelodysplastic syndrome. Bone. 1996; 19(4): 401-5.
32. Deeg HJ, Appelbaum FR. Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Leuk Res. 2000; 24(8): 653-63.
33. Deeg HJ, Beckham C, Loken MR, Bryant E, Lesnikova M, Shulman HM, et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma. 2000; 37(3-4): 405-14.
34. Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science. 2008; 322(5909): 1861-5.
35. Tzeng YS, Li H, Kang YL, Chen WC, Cheng WC, Lai DM. Loss of Cxcl12/Sdf-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression. Blood. 2011; 117(2): 429-39.
36. Kortesidis A, Zannettino A, Isenmann S, Shi S, Lapidot T, Gronthos S. Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood. 2005; 105(10): 3793-801.
37. Herberg S, Fulzele S, Yang N, Shi X, Hess M, Periyasamy-Thandavan S, et al. Stromal cellderived factor-1ffpotentiates bone morphogenetic protein-2-stimulated osteoinduction of genetically engineered bone marrowderived mesenchymal stem cells in vitro. Tissue Eng Part A. 2013; 19(1-2): 1-13.
38. Flores-Figueroa E, Montesinos JJ, Flores-Guzmán P, Gutiérrez-Espíndola G, Arana-Trejo RM, Castillo-Medina S, et al. Functional analysis of myelodysplastic syndromesderived mesenchymal stem cells. Leuk Res. 2008; 32(9): 1407-16.
39. Matsuda M, Morita Y, Hanamoto H, Tatsumi Y, Maeda Y, Kanamaru A. CD34+ progenitors from MDS patients are unresponsive to SDF-1, despite high levels of SDF-1 in bone marrow plasma. Leukemia. 2004; 18(5): 1038-40.
40. Ding L, Saunders TL, Enikolopov G, Morrison SJ. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature. 2012; 481(7382): 457-62.
41. Stopp S, Bornhäuser M, Ugarte F, Wobus M, Kuhn M, Brenner S, Thieme S. Expression of the melanoma cell adhesion molecule in human mesenchymal stromal cells regulates proliferation, differentiation, and maintenance of hematopoietic stem and progenitor cells. Haematologica. 2013; 98(4): 505-13.
42. Tachezy M, Zander H, Marx AH, Stahl PR, Gebauer F, Izbicki JR, et al. ALCAM (CD166) expression and serum levels in pancreatic cancer. PLoS One. 2012; 7(6): e39018.
43. Walenda T, Bork S, Horn P, Wein F, Saffrich R, Diehlmann A, et al. Co-culture with mesenchymal stromal cells increases proliferation and maintenance of haematopoietic progenitor cells. J Cell Mol Med. 2010; 14(1-2): 337-50.
44. Quian H, Le Blanc K, Sigvardsson M. Primary mesenchymal stem and progenitor cells from bone marrow lack expression of CD44 protein. J Biol Chem. 2012; 287: 25795-807.
45. Mhyre AJ, Marcondes AM, Spaulding EY, Deeg HJ. Stroma-dependent apoptosis in clonal hematopoietic precursors correlates with expression of PYCARD. Blood. 2009; 113(3): 649-58.
46. Matsuoka A, Tochigi A, Kishimoto M, Nakahara T, Kondo T, Tsujioka T, et al. Lenalidomide induces cell death in an MDSderived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia. 2010; 24(4): 748-55.
47. Munemasa S, Sakai A, Kuroda Y, Okikawa Y, Katayama Y, Asaoku H, et al. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol. 2008; 33(1): 129-36.
48. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010; 16(11): 2927-31.
49. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009; 113(24): 6206-14.
50. Ximeri M, Galanopoulos A, Klaus M, Parcharidou A, Giannikou K, Psyllaki M, et al. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica. 2010; 95(3): 406-14.